obviously business outlook section is reassuring for any investors
The Company also intends to reinvigorate revenue opportunities from the sale of products. This includes
launching FebriDx in the US with first commercial orders expected by the end of CY2023 and selling other
women’s health, STI and infectious disease products through the recently established US sales channel. In
addition, Lumos expects to grow sales of FebriDx in Europe and other markets in light of the renewed
interest in the product following the FDA clearance and the expanded distribution coverage provided by
Henry Schein and other distribution partners.
Ann: FY23 Full Year Results Announcement, page-2
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $24.06M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.7¢ | $191.0K | 3.799M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 194776 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 104662 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| LDX (ASX) Chart |